TL;DR
- •Cymbalta (duloxetine) is an SNRI antidepressant; Lyrica (pregabalin) is a gabapentinoid anticonvulsant. Both are FDA-approved for fibromyalgia AND diabetic peripheral neuropathy, but they work through entirely different mechanisms.
- •Cymbalta also treats depression and generalized anxiety, so it is often preferred when a mood or anxiety disorder accompanies the pain.
- •Lyrica also treats certain seizures and post-herpetic neuralgia, and is frequently chosen when sleep disturbance or anxiety-driven pain amplification is prominent because of its calming, sedating effect.
- •Head-to-head, neither is reliably superior for pain — guideline reviews place both among first-line agents for neuropathic pain and fibromyalgia, with the choice driven by comorbidities and side-effect tolerance.
- •Cymbalta can cause nausea, increased blood pressure, and a difficult discontinuation syndrome; Lyrica can cause sedation, dizziness, weight gain, peripheral edema, and is a Schedule V controlled substance with misuse potential.
- •They are commonly combined for refractory neuropathic pain, since the SNRI and gabapentinoid mechanisms are complementary.
- •For patients whose pain is intertwined with treatment-resistant depression, at-home ketamine offers a separate mechanism (NMDA/glutamate) with emerging evidence in both mood and certain chronic-pain states.
Side by side
Cymbalta
Duloxetine
SNRI (serotonin-norepinephrine reuptake inhibitor)
What it treats
Fibromyalgia, Diabetic peripheral neuropathy, Chronic musculoskeletal pain, Major depression, Generalized anxiety disorder
Mechanism
Blocks reuptake of both serotonin and norepinephrine. The norepinephrine effect enhances descending inhibitory pain pathways in the spinal cord, producing analgesia independent of its antidepressant action.
Strengths
- •Dual-purpose — treats comorbid depression and anxiety alongside pain
- •FDA-approved for fibromyalgia, diabetic neuropathy, and chronic musculoskeletal pain
- •Once-daily dosing, no controlled-substance scheduling
- •Strong choice when mood symptoms accompany a chronic-pain condition
Limitations
- •Nausea (often early and transient), dry mouth, constipation
- •Can raise blood pressure — caution in hypertension
- •Discontinuation syndrome can be difficult (taper required)
- •Sexual dysfunction and sweating, as with other SNRIs
Lyrica
Pregabalin
Gabapentinoid (alpha-2-delta calcium-channel ligand, Schedule V)
What it treats
Fibromyalgia, Diabetic peripheral neuropathy, Post-herpetic neuralgia, Neuropathic pain from spinal cord injury, Adjunct for partial-onset seizures
Mechanism
Binds the alpha-2-delta subunit of voltage-gated calcium channels, reducing release of excitatory neurotransmitters (glutamate, substance P, norepinephrine) in hyperexcitable neurons — dampening the amplified pain signaling of neuropathic and central-sensitization states.
Strengths
- •Effective for neuropathic pain with a calming, sleep-promoting effect
- •FDA-approved across multiple neuropathic-pain indications plus fibromyalgia
- •Helpful when sleep disturbance or anxiety amplifies the pain
- •Predictable, dose-dependent response; no antidepressant onset lag for pain relief
Limitations
- •Sedation, dizziness, and cognitive fog ("brain fog") are common
- •Weight gain and peripheral edema with longer use
- •Schedule V controlled substance — misuse potential and taper needed to avoid withdrawal
- •Does not treat depression; dose adjustment required in renal impairment
Which one for your situation?
If:
Chronic pain with comorbid depression or generalized anxiety
Verdict:
Cymbalta — treats the mood/anxiety disorder and the pain together with one medication
If:
Neuropathic pain with prominent insomnia or anxiety-driven pain amplification
Verdict:
Lyrica — its sedating, calming effect helps sleep and the wind-up component of pain
If:
Hypertension or cardiovascular concern
Verdict:
Lyrica — Cymbalta can raise blood pressure; the gabapentinoid does not
If:
Weight gain or daytime sedation must be avoided (e.g., safety-sensitive work)
Verdict:
Cymbalta — Lyrica more often causes sedation, cognitive fog, and weight gain
If:
History of substance misuse
Verdict:
Cymbalta — not a controlled substance; Lyrica is Schedule V with misuse potential
If:
Partial response to one agent for refractory neuropathic pain
Verdict:
Combine — the SNRI and gabapentinoid mechanisms are complementary and frequently used together under supervision
Where ketamine fits
Where chronic pain is intertwined with treatment-resistant depression, ketamine offers a third mechanism distinct from both an SNRI and a gabapentinoid. Its NMDA/glutamate action has the strongest evidence in treatment-resistant depression and emerging evidence in certain central-sensitization and neuropathic-pain states. It is best viewed as an option for the mood component or refractory cases — not a first-line replacement for Cymbalta or Lyrica in routine neuropathic pain.
Lyrica produces pain relief within days of reaching an effective dose. Cymbalta's analgesic effect builds over 1-4 weeks (and its antidepressant effect over 4-6 weeks). Sublingual ketamine produces mood response within hours of the first session.
5-minute screening · Reviewed by a board-certified physician · FL & NJ
Frequently asked
Is Cymbalta or Lyrica better for fibromyalgia?
Both are FDA-approved for fibromyalgia, and head-to-head neither is reliably superior — guideline reviews place both among first-line agents with comparable, modest effect sizes. The choice is driven by your other symptoms: Cymbalta if depression or anxiety accompany the pain; Lyrica if sleep disturbance or pain-amplifying anxiety is prominent. Many patients try one, and switch or combine if the response is inadequate.
Can I take Cymbalta and Lyrica together?
Yes — the combination is common for refractory neuropathic pain and fibromyalgia because the SNRI mechanism (descending inhibition) and the gabapentinoid mechanism (reduced excitatory neurotransmitter release) are complementary. It does require physician supervision to manage additive side effects like dizziness and sedation, and to taper appropriately if either is stopped.
Is Lyrica addictive?
Lyrica (pregabalin) is a Schedule V controlled substance with recognized misuse potential, particularly in people with a history of substance use disorder. Physical dependence can develop, so it should be tapered rather than stopped abruptly to avoid withdrawal. Cymbalta is not a controlled substance, though it also requires a taper because of its own discontinuation syndrome.
Which is easier to stop taking?
Both require a gradual taper. Cymbalta has a well-known discontinuation syndrome (dizziness, nausea, "brain zaps," irritability) if stopped abruptly. Lyrica withdrawal can include anxiety, insomnia, and sweating, and as a controlled substance it warrants a structured taper. Neither should be discontinued suddenly — work with your prescriber on a schedule.
How does ketamine fit if neither controls my pain and mood?
When chronic pain is tangled up with treatment-resistant depression, ketamine offers a separate mechanism (NMDA/glutamate) from both an SNRI and a gabapentinoid. Its strongest evidence is in treatment-resistant depression, with emerging data in certain central-sensitization pain states. It is not a first-line replacement for Cymbalta or Lyrica in routine neuropathic pain, but it can be a meaningful option for the mood component or refractory cases. A physician reviews your full picture during consultation.
References
- Lunn MP et al. 2014, Cochrane Database of Systematic Reviews. Cochrane review found duloxetine effective for painful diabetic neuropathy and fibromyalgia pain, with a small-to-moderate analgesic benefit partly independent of its effect on mood. PMID 24385423
- Finnerup NB et al. 2015, Lancet Neurology. Systematic review and meta-analysis recommended SNRIs (including duloxetine) and gabapentinoids (including pregabalin) as first-line pharmacotherapy for neuropathic pain in adults. PMID 25575710
- Derry S et al. 2019, Cochrane Database of Systematic Reviews. Cochrane review of pregabalin for neuropathic pain in adults found evidence of efficacy in diabetic neuropathy, post-herpetic neuralgia, and central neuropathic pain, supporting its first-line role alongside SNRIs. PMID 30673120
- Murrough JW et al. 2013, American Journal of Psychiatry. Ketamine RCT in treatment-resistant depression — 64% response vs 28% placebo, relevant when chronic pain is intertwined with treatment-resistant mood symptoms. PMID 23982301